Revere Data™ Expands Biopharm Coverage to Include Historical Drug Sales Data and Patent Expiration Dates ::
February 07, 2008
New York -- Revere Data, LLC, a fast-growing research provider of datafeed, software, index and ETF services, today announced a significant enhancement to its biopharmaceutical coverage. In addition to mapping the drug pipelines, disease sector participation, clinical stages of development, FDA catalyst events, and key strategic partnerships for virtually all biopharmaceutical companies trading in the United States and Canada, Revere customers now have access to historical drug sales data and patent expiration dates for more than one hundred blockbuster drugs.
The biopharmaceutical industry is intensely competitive, dynamic and growing. Today’s announcement marks the first phase of Revere Data’s coverage of drug sales and patent expiration dates, improving investors’ ability to anticipate the opportunities and challenges facing biopharm companies.
“The vast amount of data and Wall Street opinions on the biopharmaceutical industry can be overwhelming, confusing, and sometimes misleading,” noted Jeremy Zhou, Director of Healthcare for Revere Data. “At Revere we strive to help investors get straight to the essentials, and by expanding our coverage to drug sales and patent expiration, customers now have improved visibility into any biopharm company’s near, medium and longer-term potentials and risks.”
“Our core focus has always been to deliver significant value to our customers by actively and strategically expanding our data coverage,” said Kevin E. O’Brien, Chief Executive Officer of Revere Data. “With the addition of drug sales and patent expiration, we can now better equip our customers with the tools and data to stay ahead of the curve in a dynamic, competitive industry.”
Revere’s patented sector classification system, key business relationships, and Healthcare Events are all available in datafeeds and through the company’s flagship Revere Research service. Customers include sell-side agency and proprietary traders, buy-side traders, hedge funds, portfolio managers, and equity analysts, along with professionals at major corporations looking for product information and competitive advantages.
The biopharmaceutical industry is intensely competitive, dynamic and growing. Today’s announcement marks the first phase of Revere Data’s coverage of drug sales and patent expiration dates, improving investors’ ability to anticipate the opportunities and challenges facing biopharm companies.
“The vast amount of data and Wall Street opinions on the biopharmaceutical industry can be overwhelming, confusing, and sometimes misleading,” noted Jeremy Zhou, Director of Healthcare for Revere Data. “At Revere we strive to help investors get straight to the essentials, and by expanding our coverage to drug sales and patent expiration, customers now have improved visibility into any biopharm company’s near, medium and longer-term potentials and risks.”
“Our core focus has always been to deliver significant value to our customers by actively and strategically expanding our data coverage,” said Kevin E. O’Brien, Chief Executive Officer of Revere Data. “With the addition of drug sales and patent expiration, we can now better equip our customers with the tools and data to stay ahead of the curve in a dynamic, competitive industry.”
Revere’s patented sector classification system, key business relationships, and Healthcare Events are all available in datafeeds and through the company’s flagship Revere Research service. Customers include sell-side agency and proprietary traders, buy-side traders, hedge funds, portfolio managers, and equity analysts, along with professionals at major corporations looking for product information and competitive advantages.
PR Contact: Bill Mendel
Company: Mendel Communications LLC
Phone: (212) 397-1030
E-mail: bill@mendelcommunications.com
Research Contact: Brian Hill, CFA
Title: Director, Research
Company: Revere Data, LLC
Phone: (866) 738-3739 x105
E-mail: bhill@reveredata.com